Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,371 | -507 | -492 | -4,938 | -5,052 |
| Depreciation Amortization | 625 | 423 | 216 | 1,028 | 812 |
| Accounts receivable | -1,921 | -2,631 | -1,405 | 2,255 | 1,907 |
| Accounts payable and accrued liabilities | -3,329 | -2,127 | -2,333 | 553 | -481 |
| Other Working Capital | -1,977 | -2,480 | -643 | 4,562 | 5,474 |
| Other Operating Activity | 8,757 | 7,353 | 4,952 | 3,657 | 3,808 |
| Operating Cash Flow | $3,526 | $31 | $295 | $7,117 | $6,468 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -74 | -53 | -41 | -143 | -122 |
| Investing Cash Flow | $-74 | $-53 | $-41 | $-143 | $-122 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,641 | 598 | 0 | N/A | N/A |
| Other Financing Activity | -20 | -16 | -14 | -90 | -14 |
| Financing Cash Flow | $1,621 | $582 | $-14 | $-90 | $-14 |
| Beginning Cash Position | 27,325 | 27,325 | 27,325 | 20,441 | 20,441 |
| End Cash Position | 32,398 | 27,885 | 27,565 | 27,325 | 26,773 |
| Net Cash Flow | $5,073 | $560 | $240 | $6,884 | $6,332 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,526 | 31 | 295 | 7,117 | 6,468 |
| Capital Expenditure | -94 | -53 | -41 | -148 | -127 |
| Free Cash Flow | 3,432 | -22 | 254 | 6,969 | 6,341 |